News

This segment of Maloney’s interview at the SDPA Fall Conference discussed off-label uses of JAK inhibitors and other treatment news in dermatology.

Integrating facilitated telemedicine into opioid treatment programs led to SVR, improved patient satisfaction, and long-term health gains 5 years post-cure.

Adding evolocumab to existing lipid-lowering therapies significantly reduced first MACE risk, highlighting its efficacy in reducing cardiovascular mortality.

Phase 3 LIBERTY AIMS data reveal significant reductions in nasal polyps, surgery, and steroid use in patients with AFRS, a challenging CRSwNP subtype.

Neuen and Gale break down groundbreaking insights on Alport syndrome and glomerular diseases, including RaDaR registry data.

Maloney speaks in this interview at the SDPA Fall Conference about off-label uses of JAK inhibitors in dermatology.

Dupilumab maintained histologic and endoscopic improvements across all pediatric age groups with EoE, according to Joshua Wechsler, MD.

Research presented at the American Heart Association Scientific Sessions 2025 has emphasized the progress which still needs to be made in treating CHD.

Dale Lee, MD, told HCPLive that regular monitoring and potential psychosocial support are important to help children with celiac disease maintain a gluten-free diet.

HCPLive highlights key pediatric gastroenterology updates from NASPGHAN 2025, with continuing coverage to follow.

Discover groundbreaking findings from the FINE-ONE trial on finerenone, offering hope for type 1 diabetes patients with CKD.

Sparsentan shows superior proteinuria reduction in pediatric FSGS patients, setting the stage for potential FDA approval.

A post hoc analysis of the phase 2b SYMMETRY trial highlights efruxifermin’s impact on overall fibrosis burden and septa area.

Discover groundbreaking insights on SGLT2 inhibitors and their impact on kidney health, cardiovascular outcomes, and patient care at ASN Kidney Week.

New research shows nearly all adults with hypertensive chronic kidney disease benefit from a <120 mm Hg target.

Renata Block spoke at the 2025 SDPA Fall Conference about her session on the use of artificial intelligence tools in clinical practice.

At ACAAI 2025, Shaker dispels epinephrine myths, emphasizing that it is safe, effective, and underused in anaphylaxis care.

Data presented at NASPGHAN 2025 revealed odevixibat demonstrated sustained improvements in sleep and caregiver-reported QOL in patients with Alagille syndrome through 96 weeks.

SGLT2 inhibitors show significant kidney protection for chronic kidney disease regardless of diabetes status or albumin levels.

In the phase 2b VANTAGE trial, volixibat shows meaningful gains in fatigue, sleep, and itch relief in PBC patients.

At ACAAI 2025, Shaker highlighted evolving therapies and real-world barriers that continue to limit optimal anaphylaxis management.

The SDPA president, Sarah Vicari, spoke at the 2025 SDPA Fall Conference about the conference and its significance.

New data on daily fish oil supplementation prompts discussions on clinical recommendations.

The new guidance seeks to aid patient selection, comorbidity management, and monitoring the safety and effectiveness of semaglutide for MASH.

At ACAAI 2025, Durban breaks down natural allergy treatments and separates myths from evidence.

Shroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.

Cheung explores the effect of sparsentan on urinary biomarkers in treatment-naive patients with IgA nephropathy.